pramoxine/mineral oil/zinc oxide rectal (OTC)

Brand and Other Names:Tucks Hemorrhoidal Ointment
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

pramoxine/mineral oil/zinc oxide rectal

topical ointment

  • 1%/46.6%/12.5%

Topical Pain

For symptomatic relief of the discomfort associated with hemorrhoids, perianal itchin, or irritation

Apply externally to affected area up to 5 times daily PRN

Administration

When practical, cleanse the affected area with mild soap and warm water and rinse thoroughly and gently dry by patting or blotting with toilet tissue or a soft cloth before application

Clean dispensing cap after every use

Dosage Forms & Strengths

pramoxine/mineral oil/zinc oxide rectal

topical ointment

  • 1%/46.6%/12.5%

Topical Pain

For symptomatic relief of the discomfort associated with hemorrhoids, perianal itching or irritation

<12 years: Safety and efficacy not established

≥12 years: Apply externally to affected area up to 5 times daily PRN

Administration

When practical, cleanse the affected area with mild soap and warm water and rinse thoroughly and gently dry by patting or blotting with toilet tissue or a soft cloth before application

Clean dispensing cap after every use

Next:

Interactions

Interaction Checker

and pramoxine/mineral oil/zinc oxide rectal

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (4)

                • beta carotene

                  mineral oil decreases levels of beta carotene by drug binding in GI tract. Use Caution/Monitor.

                • digoxin

                  mineral oil decreases levels of digoxin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                • levonorgestrel oral/ethinylestradiol/ferrous bisglycinate

                  mineral oil decreases levels of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely.

                • vitamin D

                  mineral oil will decrease the level or effect of vitamin D by Other (see comment). Use Caution/Monitor. Avoid concomitant use of mineral oil and vitamin D supplements to avoid risk of decreased absorption of vitamin D. Applies to only oral administration of these agents.

                Minor (22)

                • antithrombin alfa

                  mineral oil decreases levels of antithrombin alfa by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • antithrombin III

                  mineral oil decreases levels of antithrombin III by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • argatroban

                  mineral oil decreases levels of argatroban by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • bemiparin

                  mineral oil decreases levels of bemiparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • bivalirudin

                  mineral oil decreases levels of bivalirudin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • dabigatran

                  mineral oil decreases levels of dabigatran by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • dalteparin

                  mineral oil decreases levels of dalteparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • docusate

                  docusate increases levels of mineral oil by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • enoxaparin

                  mineral oil decreases levels of enoxaparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • ethinylestradiol

                  mineral oil decreases levels of ethinylestradiol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • fondaparinux

                  mineral oil decreases levels of fondaparinux by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • heparin

                  mineral oil decreases levels of heparin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • mestranol

                  mineral oil decreases levels of mestranol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • phenindione

                  mineral oil decreases levels of phenindione by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • protamine

                  mineral oil decreases levels of protamine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfadiazine

                  mineral oil decreases levels of sulfadiazine by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfamethoxazole

                  mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • sulfisoxazole

                  mineral oil decreases levels of sulfisoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin A

                  mineral oil decreases levels of vitamin A by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin E

                  mineral oil decreases levels of vitamin E by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • vitamin K1 (phytonadione)

                  mineral oil decreases levels of vitamin K1 (phytonadione) by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                • warfarin

                  mineral oil decreases levels of warfarin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                Previous
                Next:

                Adverse Effects

                Frequency Not Defined

                Irritation

                Pruritus

                Previous
                Next:

                Warnings

                Contraindications

                Hypersensitivity

                Cautions

                For external use only

                Do not use in the eyes

                Do not use on blistered or broken skin

                If condition worsens, or if symptoms persist for >7 days or clear up and occur again within a few days, discontinue and reassess therapy

                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy Category: Undetermined, caution advised

                Lactation: Unknown if excreted in breast milk, caution advised

                Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Pramoxine: local anesthetic due to inhibition of conduction of nerve impulses from sensory nerves, resulting from an alteration of the cell membrane permeability to ions

                Zinc oxide: antiseptic and protectant properties

                Absorption

                Minimal

                Onset: 3-5 min

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.